chrisvoncsefalvay/vaers-outcomes huggingface dataset:
got both doses of vaccine while pregnant; This spontaneous prospective pregnancy case was reported by a physician and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (got both doses of vaccine while pregnant) in a 32-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011J20A and 028L20A) for COVID-19 vaccination.     The patient's past medical history included Alcohol use (0-1 drink per week). Concomitant products included PRENATAL + DHA for Pregnancy.   On 06-Jan-2021 at 10:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021 at 10:10 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 02-Jun-2020 and the estimated date of delivery was 09-Mar-2021. On 06-Jan-2021 at 10:10 AM, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (got both doses of vaccine while pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  thirty-first week of the pregnancy. The delivery occurred on an unknown date, which was reported as Unknown. For neonate 1, The outcome was reported as Unknown. On 03-Feb-2021 at 10:10 AM, MATERNAL EXPOSURE DURING PREGNANCY (got both doses of vaccine while pregnant) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 02-Jul-2020, Pregnancy test: positive (Positive) positive. In August 2020, Prenatal screening test: negative (Negative) First trimester-Negative. In October 2020, Ultrasound scan normal: normal (normal) Normal. On 15-Dec-2020, Glucose tolerance test: 78 (Inconclusive) 78. On 21-Jan-2021, Ultrasound scan normal: normal (normal) Normal.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Action taken with mRNA-173 in response to the event was not applicable.  No treatment information was provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 03-Feb-2021: Internal review conducted on 21-JUL-2021, resulted in updates to the pregnancy details, patient and vaccine information, event coding to "maternal exposure during pregnancy", event onset date and iNarrative supplement.
On the night of the 27th, approx. at 5 pm, my heart was racing and tachycardia and Afib. That's happened before but it's been very mild. It never lasted more than a couple minutes. That evening, the scale went from 1-2 to 100. and it lasted for 2 ½ hours and I called 911 and they took me to the hospital. I got to the hospital and what they did, they did all the blood tests. They put me on Diltiazem, 5% solution through IV bag. And so, they monitored me all night and kept me in the ER because there was no room in the hospital until the next day until 10-11am. Things finally started settling down, but they weren't normal until about that time. I was released that afternoon and the doctor had time to see me around 3pm while I was at the hospital. When I was released, on the 28th, I saw the doctor. He increased Flecainide from 100 to 200mg in the evening and gave me diltiazem just in case that happened again. And that's how we left it until 2/23 when I had an event just the same as the first. Around 5-6 pm, so I took the diltiazem as instructed. And I remembered to wait a couple hours and things should be back to normal. I waited 2 ½ hours and nothing was back to normal and called 911 again. So, I was in the hospital again, and I told the guy what I did, and they monitored for an hour and let me leave the hospital at 12am because I was back to normal, and the medication did take care of the situation. So, I saw my doctor on 2/24 and we needed a new plan. And so, at that point in time, he took me off the Flecainide and put me on metoprolol 25mg once daily. Also put me on Mullaq 400mg twice daily. and I started the next day when I picked it up at the pharmacy. And that was the plan to keep things stabilized. Then at that meeting, he mentioned to do an atrial fibrillation ablation. And so that's the way it stayed until a follow up with July. We talked about the ablation more and I went back and had the ablation on 9/21/2021. So far so good.
persistent swelling/redness of injection site area Narrative:  Developed a dime-sized area of swelling/redness over injection site that started on the same day as the vaccination and lasted for another 5 days. Area was no indurated or warm to touch. There was no associated rash, pruritus, or sloughing. He denies experiencing other adverse effects. He did not try or apply any therapies.
FLUSH; LIGHT HEADED, DIZZINESS; VERY THIRSTY; FEELING OVERHEATED; This spontaneous report received from a patient concerned a 46 year old female. The patient's height, and weight were not reported. The patient's past medical history included carpel tunnel surgery, right ankle surgery, weight loss surgery and chest reduction surgery, pneumonia, tonsillectomy, and liposuction, and concurrent conditions included hypertension, chronic rhinitis, chronic migraine, and allergy to pollens. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A, and  expiry: UNKNOWN) dose was not reported, administered on 12-APR-2021 08:30 for prophylactic vaccination. Concomitant medications included cannabis sativa for drug used for unknown indication, lisinopril for hypertension, zolpidem tartrate for sleep, amoxicillin/clavulanic acid, botulinum toxin type a, and montelukast non-company. On 12-APR-2021, the subject experienced flush. On 12-APR-2021, the subject experienced light headed, dizziness. On 12-APR-2021, the subject experienced very thirsty. On 12-APR-2021, the subject experienced feeling overheated. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from flush, light headed, dizziness, very thirsty, and feeling overheated. This report was non-serious.
Blood blister under his tongue the size of a pencil eraser where tongue connects to bottom of mouth; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD BLISTER (Blood blister under his tongue the size of a pencil eraser where tongue connects to bottom of mouth) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in November 2020.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, the patient experienced BLOOD BLISTER (Blood blister under his tongue the size of a pencil eraser where tongue connects to bottom of mouth). At the time of the report, BLOOD BLISTER (Blood blister under his tongue the size of a pencil eraser where tongue connects to bottom of mouth) had resolved. Unknown      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 23-Jun-2021: Updated event outcome blood blister from Unknown to Recovered
No adverse effects reported; The patient was inadvertently administered a dose of GARDASIL 9, that was improperly stored.; This spontaneous report has been received from a registered nurse regarding to a patient of unknown age and gender. The patient's concurrent condition, medical history, concomitant medication, drug allergies or reactions were not provided.   On 25-APR-2019, the patient was vaccinated with an improperly dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9), (dose and anatomical location of vaccine were not provided) that could be one of these products; lot # N022583 and expiration date 20-JUN-2020; Lot # R020200 and expiration date 05-MAY-2021 or lot # 1586752 and expiration date 16-FEB-2021 for prophylaxis. The doses of the vaccines experienced a temperature excursion at (29.9 ° F) for a time frame of 19 minutes. The highest temperature excursion was above 47.6 °F (9 Celsius degrees) for 1 hour. The lowest temperature excursion was below 34.5°F (2 Celsius degrees) for 35 minutes. This report was called because of a data logger. There was no adverse effect reported.
Approx 30-45 min later noted metallic taste in mouth. Approximately 2 hrs later eyes (upper and lower lids) swollen, lips also swollen tightness in throat, trouble swallowing - used prefilled EPIPEN. Approx 30 min later, took 50 mg BENADRYL. Repeated 50 mg BENADRYL again 90 min later (felt throat tight again). Recovered.
Pt received highly recommended vaccinations of Meningococcal AND HPV into right deltoid. The first 12 hours very sore with localized redness and some swelling; ice compress and ibuprofen choice of treatment. 48 hours post injection the site is very painful, red, swollen. A new isolated area below primary site is now becoming inflamed with shooting pain radiating to right ring finger. Also discomfort to right pectoralis. No s/s of dyspnea,pallor,or parasthesia; Benadryl 25mg by mouth administered along with thin topical benadryl cream.
Onset of severe HA with body ache; approx 24 hours post vaccination followed by soreness, swelling, red bumps at injection site. Itchy rash spread down (R) arm and across chest over next few hours. One or two itchy spots on face, mainly arms & trunk. Rash consists of small "prickly pimples", not hives. Rash is improving, worse at night. Patient reports her mother told her, after, Tdap administered that she had a high fever (105) and a rash following dose #1 of DTaP at age 2 months. This history was unknown to patient at time of Tdap receipt.
Shortly after receiving vaccine developed flushing, numbness, tingling, coughing, horseness, wheezing, difficulty breathing. Transported to ER
pt recv vax; syncope p/ vax; also mild transient erythema on abd; unclear vasovagal episode from needle or from vax;
Pt had syncope immediately after vaccine. Fell off bench and hit head on floor. complete loss of consciousness. pt mother states that has never happened before. pt regained consciousness in less than a minute. ice pack applied. pt mom will follow up with pcp. Another patient stated child was having a seizure but I believe they were just jerking movements from syncope. Mom and I did not witness event as we were in the vaccination booth and no video footage on cameras. Mom states no history of seizures.
Migraine headache, vomiting 2pm day of Overnight fever 101.5
Headache, body aches, fever, chills, nausea, injection site swelling and arm pain.
Cold sweat; Feeling overheated; Sudden fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8733) via an unspecified route of administration in the left arm on 03Apr2021 at 10:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN), acetylsalicylic acid;caffeine;paracetamol (EXCEDRIN) and melatonin (MANUFACTURER UNKNOWN), all from unknown dates for unknown indications. The patient previously received codeine (MANUFACTURER UNKNOWN) and experienced drug allergy.  The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021 at 15:00, the patient experienced cold sweat though feeling overheated and sudden fatigue. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events cold sweat, feeling overheated and sudden fatigue were recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Information has been received from a physician concerning her son with no medical history and no known allergies who in approximately August 2005, at 4 weeks of age, was vaccinated in the thigh with a second dose of Recombivax HB. In approximately August 2005, post vaccination, the patient experienced a rash a the injection site. The child's doctor prescribed oral BENADRYL, but the child did not need to use it. She reported that her child gets a rash at the injection site from all the childhood vaccines he receives and they are trying to rule out an allergy to latex. The child has fully recovered. Medical attention was sought. No product quality complaint was involved. Additional information is not expected.
Participant is 17years of age and should not have been administered the Moderna vaccine according to the manufactuer's guidelines.  The participant sat in post op for 15 minutes with no adverse reaction. Mother was present the entire time.
This spontaneous report was received from a healthcare worker regarding an unknown number of patients. The patients demographics were unknown. There was no pertinent medical history and drug reaction or allergies of the patients reported. On an unknown date since APR-2014, an unknown number of patients was vaccinated with GARDASIL (dose, route, product lot and expiry date was not reported) that had been improperly stored. No adverse effects reported. The reporter stated that M-M-R II was not improperly stored. There was no product quality complaint involved. This is one of the several reports from the same reporter. Additional information has been requested.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jan-2021 at 9:13 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 11-Jan-2021 at 9:13 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 76.66 for dose administered on 11-JAN-2021. No concomitant medications were reported. Batch number 041L20A underwent temperature excursion on 11-JAN-2021 with temperature 35 Fahrenheit from 02:00 PM. This vial was moved to fridge on 08-JAN-2021 and beyond use date for the vial was reported as 07-FEB-2021. Product moved to clinic on 11-JAN-2021. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour. No treatment medications were reported.   This case was linked to MOD-2022-566976 (Patient Link).
1 day p/vax pt devel numbness of the rt wrist & wrist drop;pt dx w/saturday night synd w/resultant neuropathy unrelated to vax;
pt recv vax SEP96 & devel a red, swollen, painful area the size of a golf ball @ inj site;
I experienced fever; chills; moderate arm pain; substantial hair loss; This is a spontaneous report from a contactable consumer (patient). A 56-years-old non pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, Batch/Lot Number: EW0178, Expiry date was not reported). via an unspecified route of administration, administered in Arm Left on Jun2021 (at the age of 56 years old) as DOSE 1, SINGLE for covid-19 immunisation. The patient's medical history includes Prior to vaccination, the patient was diagnosed with COVID-19. Allergies: penicillin and morphine from an unknown date and unknown if ongoing. Since the vaccination, the patient has not been tested for COVID-19. The patient had not received any other vaccine within 4 weeks. The patient has received Occasional vitamin supplement as other medication in last two weeks. On the first 24 hours patient experienced fever and chills in addition to moderate arm pain. Beginning 2-3 weeks after the vaccine, patient have been experiencing fairly substantial hair loss. Patient received no treatment for the events. The outcome for the events was not recovered.
Patient arrived at the clinic for their second dose. They received an initial dose of Pfizer on 2/26/2021. The received a second dose of Moderna 3/19/2021. Per CDC guidance, In exceptional situations in which the vaccine product given for the first dose cannot be determined or is no longer available, any available mRNA COVID-19 vaccine may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 vaccination series. This patient received the 2nd dose at 21 days. Patient was reached at 5:07pm. She denied any adverse affects and agreed to seek medical attention if she experienced an shortness of brealth, fast heart beat, full body rash, or dizziness.
Pt is 35 yo transgender (male to female) pt s/p full Pfizer COVID vaccination: dose 1 on 5/17 and dose 2 on 6/9. PMH of well-controlled HIV. HIV medications include: bicetegravir-emtricitab-tenofov. Pt presents to the ED on 8/7 with 3 day history of myalgia, fatigue, fever. Rapid COVID test results positive. Rehydrated with IV fluids and discharge home with outpatient follow-up.
left-sided migraine the following day after vaccination in which this proceeded to progress to a right-sided migraine; palpitations; shortness of breath; Initial information received on 16-Jul-2019 regarding an unsolicited valid non-serious case received from a consumer/non-hcp.  This case involves a 38 years old female patient who experienced left-sided migraine the following day after vaccination in which this proceeded to progress to a right-sided migraine, palpitations and shortness of breath, while she received vaccine DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT [TENIVAC].  The patient's past medical history included Wound (accidentally cutting mouth with piece of metal while eating salad). The patient's past medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included LISINOPRIL (LISINOPRIL) for Blood pressure measurement.  On 03-Jul-2019, the patient received 0.5 mL dose of suspect DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT lot U6091AA, expiry date: 12-OCT-2020 via intramuscular route in the left deltoid.  On an unknown date, the patient developed a non-serious left-sided migraine the following day after vaccination in which this proceeded to progress to a right-sided migraine (migraine), palpitations and shortness of breath (dyspnoea) following the administration of DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT. Returned to ER 09Jul2019 due to worsening symptoms; follow-up HCP visit with primary care on 12Jul2019.  Relevant laboratory test results included:  Blood creatinine increased - On an unknown date: 1.3  Blood pressure systolic - On an unknown date: >190.  (Other relevant tests included Chest x-ray and brain scan were negative.)  Final diagnosis was shortness of breath, palpitations and left-sided migraine the following day after vaccination in which this proceeded to progress to a right-sided migraine.  The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]).  The outcome of the events was Unknown.  Documents held by sender: none.
Reported Symptoms:  10043607:THROMBOSIS; Narrative:  Other Relevant HX:  Other:
Experienced tingling sensation in her left hand; on the left side of her face, lip and ears, towards eye and down her chin area.; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (Experienced tingling sensation in her left hand) and HYPOAESTHESIA (on the left side of her face, lip and ears, towards eye and down her chin area.) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051CJ1A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 23-Jul-2021, the patient experienced PARAESTHESIA (Experienced tingling sensation in her left hand) (seriousness criterion medically significant) and HYPOAESTHESIA (on the left side of her face, lip and ears, towards eye and down her chin area.) (seriousness criterion medically significant). At the time of the report, PARAESTHESIA (Experienced tingling sensation in her left hand) and HYPOAESTHESIA (on the left side of her face, lip and ears, towards eye and down her chin area.) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported. No treatment medication was reported.  About 20 minutes later started to experience tingling sensation in her left hand, and then numbness on the left side of her face, lip and ears, towards eye and down her chin area.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded
After shot on 9-23-11, patient said the next day her arm hurt, redness and swelling 4" x 4" occurred below the shot. She is feeling nausea and still has the swelling on 9/26/11. I informed her to put cold compress on area and to take BENADRYL.